193 related articles for article (PubMed ID: 34539821)
1. Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study.
Patrichi B; Ţăpoi C; Rogojină RŞ; Bedreagă I; Dumitrache A; Itu A; Dragomir R; Buciuc AG
Exp Ther Med; 2021 Nov; 22(5):1225. PubMed ID: 34539821
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation.
Lagreula J; de Timary P; Elens L; Dalleur O
Ther Adv Psychopharmacol; 2022; 12():20451253221112587. PubMed ID: 36051501
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong.
Lung SLM; Lee HME; Chen YHE; Chan KWS; Chang WC; Hui LMC
Asian J Psychiatr; 2018 Mar; 33():113-120. PubMed ID: 29574303
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008.
Choi HJ; Jung SH; Kang MH; Lee JS; Bae JN; Kim CE
Clin Psychopharmacol Neurosci; 2011 Apr; 9(1):17-22. PubMed ID: 23430568
[TBL] [Abstract][Full Text] [Related]
5. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders.
Thompson JV; Clark JM; Legge SE; Kadra G; Downs J; Walters JT; Hamshere ML; Hayes RD; Taylor D; MacCabe JH
J Psychopharmacol; 2016 May; 30(5):436-43. PubMed ID: 26905920
[TBL] [Abstract][Full Text] [Related]
7. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
Wu YH; Lai CY; Chang YS
Psychogeriatrics; 2015 Mar; 15(1):7-13. PubMed ID: 25515355
[TBL] [Abstract][Full Text] [Related]
10. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
Pae CU
Chonnam Med J; 2020 Sep; 56(3):157-165. PubMed ID: 33014754
[TBL] [Abstract][Full Text] [Related]
12. Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
Lin CH; Huang CJ; Lin TC; Chan HY; Chen JJ
Psychiatry Res; 2023 Dec; 330():115575. PubMed ID: 37913621
[TBL] [Abstract][Full Text] [Related]
13. Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey.
Wang J; Jiang F; Zhang Y; Cotes RO; Yang Y; Liu Z; Ning X; Liu T; Liu Y; Tang YL; Liu H
Asian J Psychiatr; 2021 Aug; 62():102742. PubMed ID: 34243064
[TBL] [Abstract][Full Text] [Related]
14. Readmission Rates of Patients Discharged on Antipsychotic Polypharmacy Compared to Antipsychotic Monotherapy.
Greer D; Parikh A; Jimenez HR
Community Ment Health J; 2023 Apr; 59(3):507-511. PubMed ID: 36242684
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.
Li Q; Xiang YT; Su YA; Shu L; Yu X; Chiu HF; Correll CU; Ungvari GS; Lai KY; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM
Aust N Z J Psychiatry; 2015 Feb; 49(2):129-36. PubMed ID: 24923760
[TBL] [Abstract][Full Text] [Related]
17. Polypharmacy Management of Antipsychotics in Patients with Schizophrenia.
Kamei H
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363541
[TBL] [Abstract][Full Text] [Related]
18. Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients.
Lassen S; Heintz T; Pedersen T; Jentz C; Nathanielsen N; Heilmann P; Sørensen LU
Int J Circumpolar Health; 2023 Dec; 82(1):2218654. PubMed ID: 37300837
[TBL] [Abstract][Full Text] [Related]
19. A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona.
Gaviria AM; Franco JG; Aguado V; Rico G; Labad J; de Pablo J; Vilella E
PLoS One; 2015; 10(10):e0139403. PubMed ID: 26427051
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland.
Jaracz J; Tetera-Rudnicka E; Kujath D; Raczyńska A; Stoszek S; Czernaś W; Wierzbiński P; Moniakowski A; Jaracz K; Rybakowski J
Pharmacol Rep; 2014 Aug; 66(4):613-7. PubMed ID: 24948062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
